Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population

AstraZeneca1 site in 1 country30,181 target enrollmentNovember 2009

ConditionsDyslipaemia Atherosclerosis Risk Increased hsCRP Inflammatory and Oxidative Status in the Spanish Population

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Dyslipaemia
Sponsor: AstraZeneca
Enrollment: 30181
Locations: 1
Primary Endpoint: Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

Registry

clinicaltrials.gov

Start Date

November 2009

End Date

October 2011

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have an Informed consent form signed when the patient accepted to participate in the study already performed.
•Spanish population between
•Data from Epidemiological studies performed after the year 2000

Exclusion Criteria

•Spanish population outside the age range
•Data from Epidemiological studies performed before the year 2000

Outcomes

Primary Outcomes

Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments

Time Frame: retrospectively

Secondary Outcomes

High sensitivity C reactive protein & CHR risk by Framingham adapted functions(retrospectively)
Lipid profile among the Spanish regions, as in the primary outcome variable(retrospectively)
Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other(prospectively)